



Balfour Capital Group Legend Biotech Corporation

Legend Biotech is a global, commercial-stage biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications. Founded in 2014 and headquartered in Somerset, New Jersey, the company operates facilities in the U.S., China, and Europe. Its flagship product, CARVYKTI® (ciltacabtagene autoleucel or cilta-cel), is a CAR-T therapy targeting B-cell maturation antigen (BCMA) for the treatment of multiple myeloma. CARVYKTI® has demonstrated significant efficacy, including a 45% reduction in the risk of death over three years in clinical studies.

1. Top 5 Competitors

Legend Biotech operates in the competitive field of cell and gene therapies. Its primary competitors include:

- Arcellx: Developing anito-cel, a CAR-T therapy for multiple myeloma.
- bluebird bio: Focuses on gene therapies for severe genetic diseases and cancer.
- Allogene Therapeutics: Specializes in allogeneic CAR-T therapies.
- Sarepta Therapeutics: Develops genetic medicines to treat rare diseases.x
- TG Therapeutics: Focuses on developing treatments for B-cell malignancies.

2. Largest Institutional Shareholders

As of the latest data:

- FMR LLC: Holds approximately 13.20 million shares, representing 3.59% ownership.
- Two Sigma Advisers LP: Increased its stake by 904.3% in Q4 2024, now owning 327,400 shares.
- State Street Corp.: Owns about 0.61% of the company.
- Polar Capital Holdings Plc: Holds approximately 0.21%.
- Sumitomo Mitsui Trust Group, Inc.: Owns around 0.09%.

Overall, institutional investors own approximately 70.89% of Legend Biotech's stock.



Balfour Capital Group Legend Biotech Corporation

3. Management Team

Legend Biotech's leadership comprises experienced professionals:

- Ying Huang, Ph.D.: Chief Executive Officer.
- Alan Bash: President of CARVYKT[®].
- Guowei Fang, Ph.D.: President of Research and Development.
- Jessie Yeung: Interim Chief Financial Officer.
- Mythili Koneru, M.D., Ph.D.: Chief Medical Officer.
- Jim Pepin: General Counsel.
- Birk Vanderweeën: Senior Vice President, Global Manufacturing & Supply.

4. Revenue

For the trailing twelve months ending March 31, 2025, Legend Biotech reported revenue of approximately \$728.3 million, marking a 107.5% year-over-year growth.

5. Institutions with Buy Recommendations:

Several institutions have issued buy recommendations for Legend Biotech:

- HC Wainwright: Reaffirmed a "Buy" rating with a \$75.00 price target.
- Truist Securities: Initiated coverage with a "Buy" rating.
- UBS: Maintained a "Buy" rating with a price target of \$81.
- TD Cowen: Adjusted price target to \$67, maintaining a "Buy" rating.
- Redburn: Initiated coverage with a "Buy" rating and an \$86 price target.



Balfour Capital Group Legend Biotech Corporation

6. Analyst Sentiment Summary

Analyst sentiment towards Legend Biotech is predominantly positive:

- Out of 41 analysts, 36 have issued "Buy" ratings, and 5 have "Hold" ratings.
- The average 12-month price target is approximately \$76.73, with estimates ranging from \$53.12 to \$95.00.

7. Insider Buying and Selling (Last 24 Months)

There is limited publicly available data on insider buying or selling by Legend Biotech's management over the past 24 months. No significant insider transactions have been reported during this period.

